COVID-19 Records

Transcript segment

Baric Transcribed Interview (Redacted), p.87 · baric_ti:utt:00775

Page text: p.87 · original PDF

Date
2026-04-10 09:00 (day precision)
Type
transcript segment · interview
recipient
Christina Salazar, Harry Kazenoff, David T. Lambeth III, William Henderson, Clark Ervin, Jake Greenberg
speaker
Ralph S. Baric
I don't believe anyone had it. I would have to review the Chinese papers again that were published. The Chinese published a couple of papers on different MERS strains. I don't think they used 422, and I don't think they made molecular clones for either of them.

In context

A single line often inverts meaning once you see what it answers, so neighbouring messages are always shown.

  1. 2026-04-10 09:00 Ralph S. Baric open
    Chuming, yes. Qibin, if he emailed me, I'm familiar with his name.
  2. 2026-04-10 09:00 Christina Salazar open
    Okay. Did you ever receive any of these viruses from --
  3. 2026-04-10 09:00 Ralph S. Baric open
    No. No one in the United States had MERS 422. We synthetically resurrected it in my lab.
  4. 2026-04-10 09:00 Christina Salazar open
    And so who had it outside of the United States?
  5. 2026-04-10 09:00 Ralph S. Baric
    I don't believe anyone had it. I would have to review the Chinese papers again that were published. The Chinese published a couple of papers on different MERS strains. I don't think they used 422, and I don't think they made molecular clones for either of them.
  6. 2026-04-10 09:00 Christina Salazar open
    Okay. And did you ever receive any biological samples by hand from any of Fang Li or Fang Li's postdocs?
  7. 2026-04-10 09:00 Ralph S. Baric open
    Fang Li sent me reagents in the mail. We had collaborative grants together, so certainly we collaborated and exchanged samples on occasion, yeah.
  8. 2026-04-10 09:00 Christina Salazar open
    Reagents of what? DC.Scheduling@LexitasLegal.com
  9. 2026-04-10 09:00 Ralph S. Baric open
    Well, the grants were formulated in such a way that he would do biochemical studies and then we would do some more validation studies in the context of live viruses.

Full conversation →